Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Radiotherapy for MIBC
NCT07053735Phase 1Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of nimotuzumab in muscle-invasive bladder cancer (MIBC), sponsored by Peking University First Hospital. Primary endpoints: Objective Response Rate at 1 year, Progression-Free Survival at 5 years and 1 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07053735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053735.